MEN2501 / Menarini, Insilico Medicine - LARVOL DELTA

??MEN2501-01?: A clinical study to test MEN2501 in patients with treatment-resistant ovarian cancer (clinicaltrialsregister.eu) - P1 | N=23 | Not yet recruiting | Sponsor: Stemline Therapeutics Inc.

New P1 trial • Oncology • Ovarian Cancer • Solid Tumor

InSilico Medicine…has received approximately HKD39 million from Menarini Group ('Menarini') as an additional milestone payment, following the completion of first-in-patient dosing in a Phase I clinical trial of MEN2501 (HKEXnews)

Financing • First-in-human • Platinum resistant • Trial status • Ovarian Cancer